Editas Medicine

Company snapshot

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 21 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Editas Medicine. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Editas Medicine.

1. Jun 5, 2026 Clinical update

   EDIT-301 — Phase 2

2. May 23, 2026 Clinical update

   EDIT-101 — Phase 2

3. May 23, 2026 Clinical update

   EDIT-301 — Phase 2

4. Jul 15, 2025 Patent grant

   Systems and methods for modulating chromosomal rearrangements

5. Jun 17, 2025 Patent grant

   CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

View all clinical trial activity →

• What is Editas Medicine?

  Editas Medicine is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker EDIT. Primary therapeutic focus areas include Leber Congenital Amaurosis 10, Sickle Cell Disease, Transfusion Dependent Beta Thalassemia. NovaPharmaNews links 3 clinical prog

• Is Editas Medicine publicly traded?

  Yes. Editas Medicine is listed with ticker EDIT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Editas Medicine develop or market?

  We link 1 drug profile(s) where Editas Medicine is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/editas-medicine#company-drugs.

• What are the latest developments for Editas Medicine?

  In the last 12 months our linked public records show 3 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does Editas Medicine focus on?

  Editas Medicine focuses on Leber Congenital Amaurosis 10, Sickle Cell Disease, Transfusion Dependent Beta Thalassemia based on our analysis of their pipeline programs and drug development activities.